KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST.
Mr. Werth, Founder and CEO of ChemWerth Inc., will discuss his background as a successful pharmaceutical executive and entrepreneur, as well as his perspective on capital markets, the biotech industry, and his vision for Cingulate. Dr. Schaffer will provide a company overview and recap recent Cingulate clinical and business updates.
The event may be viewed live on Benzinga's YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate's website at cingulate.com/investors.
Who: Cingulate Investor & Board Member Peter J. Werth and Cingulate Chairman & CEO ...